Skip to main content

Year: 2021

Taaleri continues to exit non-strategic investments – sells its stake in Oima Oy

TAALERI PLC                 PRESS RELEASE                2 DECEMBER AT 8:30 (EET) Taaleri continues to exit non-strategic investments – sells its stake in Oima Oy Taaleri continues to exit non-strategic investments in line with its strategy and sells its stake in Oima Oy. Oima is an employment and payroll administration service specializing in care and employment management. Oima is acquired by Visma, the largest software company in Northern Europe. Taaleri Plc For further information, please contact:Jorma Alanne, Managing Director, Taaleri Investments, +358 50 68 865 Taaleri in brief Taaleri is a Nordic investment and asset manager with an emphasis on renewable energy and other alternative investments. We channel capital towards economically profitable undertakings that have a lasting positive impact on the environment and society. We...

Continue reading

Sampo plc’s share buybacks 01/12/2021

SAMPO PLC                 STOCK EXCHANGE RELEASE         02/12/2021 at 08:30 am Sampo plc’s share buybacks 01/12/2021 On 01/12/2021 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  32,508 43.56 AQEU  31,004 43.55 CEUX  4,895 43.55 TQEX  105,352 43.56 XHELTOTAL 173,759 43.56  *rounded to two decimals                 On 1 October 2021, Sampo announced a share buyback programme of up to a maximum of EUR 750 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 4 October 2021,...

Continue reading

Aalberts N.V.: Aalberts ‘accelerates unique positioning’ – capital markets day

Utrecht, 2 December 2021    strategic actions 2022-2026 ° increase organic revenue growth to 4-6% annually ° increase capital expenditure to EUR 200-250 million per year ° focus on 4 technology clusters and 4 end markets ° additional divestment programme EUR 250-300 million revenue ° bolt-on acquisitions EUR 250-500 million revenue ° additional operational excellence programme ° increase SDG impact, net zero carbon in 2050 or earlier ° updated Aalberts objectives 2022-2026   Aalberts ‘accelerates unique positioning’ Aalberts will focus on 4 technology clusters with high growth potential and sustainable impact in eco-friendly buildings, semicon efficiency, sustainable transportation and industrial niches. Capital expenditure increases to EUR 200-250 million per year. Innovation expenditure increases to more than 5% of total revenue. The...

Continue reading

Albioma : Opening of the exercise period and admission to trading on Euronext Growth of the BSAAR warrants issued in 2018

Press release Paris La Défense, 02 December 2021 Opening of the exercise period and admission to trading on Euronext Growth of the BSAAR warrants issued in 2018 Albioma announces that the exercise and liquidity period for the redeemable share subscription and/or purchase warrants (BSAAR) issued in 2018 will be open from 6 December 2021 to 4 December 2024. In accordance with the terms and conditions of the BSAAR warrants, the 1,071,731 BSAAR warrants issued, currently divided among 31 subscribers (including the Chairman and Chief Executive Officer, who himself is assigned 110,650 BSAAR warrants), will be admitted to trading on Euronext Growth on 6 December 2021 under ISIN code FR0013368438. For three years, the BSAAR warrants will be exercisable at a unit price of €20.90, each BSAAR giving right to one Albioma share. The majority of the...

Continue reading

Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms

Focused medicines company delivering strong operational performance Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint Confident to grow sales 4%+ CAGR through 2026*, driven by multi-billion dollar sales from Cosentyx®, Entresto®, Kesimpta®, Zolgensma®, Kisqali® and Leqvio®** Up to 20 new assets with >1-billion dollar sales potential, set to potentially be approved by 2026, to fuel further growth through 2030 and beyond Cosentyx met primary efficacy endpoint in two hidradenitis suppurativa Ph3 studies, and ianalumab demonstrated efficacy in Ph2b Sjögren’s study1 Next-generation T-Charge™ platform validated as YTB323 showed 75% CR at 3 months in DLBCL2 and PHE885 delivered 100% BOR in multiple myeloma3 Pioneering shift to advanced technology platforms including: Targeted...

Continue reading

Notification on convocation of the Joint Stock Company “Olainfarm” Extraordinary General Meeting of Shareholders on conversion of shares

Notification on convocation of the Joint Stock Company “Olainfarm” Extraordinary General Meeting of Shareholders on conversion of shares The Management board of joint stock company “Olainfarm”, registration No. 40003007246, legal address: Rūpnīcu iela 5, Olaine, LV-2114 (hereinafter referred to as “the Company”), taking into account that:on 14 October 2021 shareholders have taken a decision on the exclusion of the shares of the Company from the regulated market; a mandatory Company’s share buy-back is currently in progress, which will end on 7 December 2021; the Management board has evaluated the Company’s and its shareholders’ costs related to the holding of shares in financial instrument accounts in banks or brokerage companies and depository; the regulatory framework provides for the possibility for the Management board of the Company...

Continue reading

21Shares and ETF Securities partner up to launch world-beating crypto ETFs and education centre

ETF Securities and 21Shares, the world’s first and largest crypto ETP provider, backed by Cathie Wood, are partnering to launch Australia’s first Bitcoin and Ethereum ETFs and a best-in-class blockchain research and education centre. Subject to regulatory approvals, the ETFS 21Shares Bitcoin ETF (EBTC) and ETFS 21Shares Ethereum ETF (EETH) will provide Australians a way to invest in Bitcoin and Ether, via funds operated by ETF Securities, the world’s first issuer of a GOLD-backed ETP, in partnership with 21Shares the world’s pioneering crypto ETP provider. Zurich-based 21Shares currently has almost $3 billion in assets under management inside its 20 European crypto ETPs and total 80 listings. The firm has managed Bitcoin and Ethereum ETPs for almost three years and created the world-first physically backed crypto ETP in 2018. Graham Tuckwell,...

Continue reading

Nokia Corporation financial calendar for 2022

Nokia Corporation Stock Exchange Release2 December 2021 at 08:00 EET Nokia Corporation financial calendar for 2022 Espoo, Finland – In this stock exchange release Nokia provides its financial calendar for 2022, which includes the planned publication dates of its financial reports. Planned publication dates for Nokia’s financial reports in 2022:report for Q4 2021 and full year 2021: 3 February 2022 report for Q1 2022: 28 April 2022 report for Q2 2022 and half-year 2022: 21 July 2022 report for Q3 2022 and January-September 2022: 20 October 2022.Publication of “Nokia in 2021“Nokia plans to publish its “Nokia in 2021” annual report, which includes the review by the Board of Directors and the audited annual accounts, during week 9 of 2022. Nokia’s Annual General MeetingNokia’s Annual General...

Continue reading

ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

GENEVA, Switzerland December 2, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced a symposium and three oral presentations on linzagolix, an oral GnRH antagonist, at the 7th Society of Endometriosis and Uterine Disorders (SEUD) Congress being held virtually and in Stockholm, Sweden as a hybrid event from December 9-11, 2021. During SEUD, ObsEva will host a live symposium entitled, “The potential of the oral GnRH antagonist: a personalized approach for women with uterine fibroids,” chaired by Professor Charles Chapron on Friday, December 10, 2021, at 1:00 p.m. CET.   Presentation details are as follows: Title: Recovery of Bone Mineral Density (BMD) after Long Term Treatment with Linzagolix in Women with Endometriosis:...

Continue reading

The new entrusted WISeKey WISe.ART NFT platform is filling up for Miami BaselWorld

The new entrusted WISeKey WISe.ART NFT platform is filling up for Miami BaselWorld Geneva, Basel, Miami, World – December 2, 2021 – WISeKey International Holding. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading cybersecurity, AI and IoT company, announces the launch of an international new collection of art NFTs during Art Basel Miami Beach week.The WISe.ART NFT gallery has opened online for the Miami Art Week with artists like Luca Bonfanti (SWITZERLAND), Vika Kova (NETHERLANDS), Marcella Moser (CANADA), Mike Nwogugu (USA), and Pedro Sandoval, a Luminaries21 leader (SPAIN). Onboarding applications are now open and our personalized service and vetting committee welcomes all artists to get in touch by registering on: https://account.wiseid.com/signup?redirect_url=https://platform.wise.art/wisekeysignupcallback/ Artworks will go on sale...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.